2020 ICER Assessments

The Institute for Clinical Economic Review (ICER) conducts cost effectiveness studies for insurers using the cost-per-QALY methodology. ICER provides guidance on its website for patients and patient advocates to provide direct input related to their experiences with the disease. Click here to provide patient input. Click here to view the topics and deadlines.

• Type 2 Diabetes: Draft Scoping Document and Research Protocol available. 11/09/2021: Draft Evidence Report. Meeting 1/20/2022: Deliberation and vote on evidence presented in ICER’s report on therapies for Type 2 Diabetes.
• Hypertrophic Cardiomyopathy: Draft Evidence Report available – Comments closed. Meeting 10/22/2021: CTAF will deliberate and vote on evidence presented in ICER’s report on therapies for obstructive hypertrophic cardiomyopathy.
• Myasthenia Gravis: Draft Evidence Report available – Comments closed. Meeting 9/24/2021: New England CEPAC will deliberate and vote on evidence presented in ICER’s report on therapies for myasthenia gravis.
• Unsupported Price Increase: 11/16/2021: Final Report.
• Asthma: Draft Evidence Report available. Model Analysis Plan available. Meeting 11/19/2021: New England CEPAC will deliberate and vote on evidence presented in ICER’s report on therapies for severe asthma.
• Fair Access: Coverage Policies in 2020: Protocol Available. 12/01/2021: Final Report.